[go: up one dir, main page]

MX2020000135A - Nuevos compuestos de quinolinona. - Google Patents

Nuevos compuestos de quinolinona.

Info

Publication number
MX2020000135A
MX2020000135A MX2020000135A MX2020000135A MX2020000135A MX 2020000135 A MX2020000135 A MX 2020000135A MX 2020000135 A MX2020000135 A MX 2020000135A MX 2020000135 A MX2020000135 A MX 2020000135A MX 2020000135 A MX2020000135 A MX 2020000135A
Authority
MX
Mexico
Prior art keywords
compounds
quinolinone compounds
new
new quinolinone
cancer
Prior art date
Application number
MX2020000135A
Other languages
English (en)
Inventor
Qian Liu
Luoheng Qin
Haibing Guo
Zhao- Kui WAN
Wing Shun Cheung
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020000135A publication Critical patent/MX2020000135A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a nuevos compuestos de quinolinona, a composiciones farmacéuticas que comprenden dichos compuestos, a procesos para la preparación de dichos compuestos y al uso de dichos compuestos como inhibidores de FGFR (receptor del factor de crecimiento fibroblástico) y a su uso en el tratamiento de enfermedades, por ejemplo, el cáncer.
MX2020000135A 2017-06-27 2018-06-26 Nuevos compuestos de quinolinona. MX2020000135A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017090267 2017-06-27
PCT/CN2018/092830 WO2019001419A1 (en) 2017-06-27 2018-06-26 NEW COMPOUNDS OF QUINOLEINONE

Publications (1)

Publication Number Publication Date
MX2020000135A true MX2020000135A (es) 2020-07-22

Family

ID=64741140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000135A MX2020000135A (es) 2017-06-27 2018-06-26 Nuevos compuestos de quinolinona.

Country Status (12)

Country Link
US (1) US11384075B2 (es)
EP (1) EP3645526B1 (es)
JP (1) JP7261752B2 (es)
KR (1) KR20200020888A (es)
CN (1) CN111032643B (es)
AU (1) AU2018291687B2 (es)
BR (1) BR112019027676A2 (es)
CA (1) CA3068081A1 (es)
ES (1) ES2996878T3 (es)
MA (1) MA49522A (es)
MX (1) MX2020000135A (es)
WO (1) WO2019001419A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113227100B (zh) * 2018-12-26 2023-05-05 詹森药业有限公司 噻吩并吡啶酮化合物
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115023420A (zh) * 2020-01-24 2022-09-06 先正达农作物保护股份公司 杀有害生物活性的稠合二环杂芳香族化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
CN100526312C (zh) 2002-08-23 2009-08-12 诺华疫苗和诊断公司 苯并咪唑喹啉酮及其应用
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
US7838527B2 (en) 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
WO2005046590A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Methods for synthesizing quinolinone compounds
JP5019884B2 (ja) 2004-02-20 2012-09-05 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 炎症プロセスおよび転移プロセスの調節
CN101218228A (zh) 2005-05-23 2008-07-09 诺瓦提斯公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式

Also Published As

Publication number Publication date
AU2018291687A1 (en) 2020-01-16
CA3068081A1 (en) 2019-01-03
EP3645526A1 (en) 2020-05-06
EP3645526C0 (en) 2024-09-04
US11384075B2 (en) 2022-07-12
BR112019027676A2 (pt) 2020-09-15
WO2019001419A1 (en) 2019-01-03
JP2020525469A (ja) 2020-08-27
US20210139470A1 (en) 2021-05-13
RU2020102926A (ru) 2021-07-27
ES2996878T3 (en) 2025-02-13
JP7261752B2 (ja) 2023-04-20
RU2020102926A3 (es) 2021-12-21
KR20200020888A (ko) 2020-02-26
AU2018291687B2 (en) 2022-07-14
CN111032643B (zh) 2023-05-30
EP3645526A4 (en) 2020-10-28
MA49522A (fr) 2020-05-06
CN111032643A (zh) 2020-04-17
EP3645526B1 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
MY199705A (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
AU2015237050A8 (en) Quinoline derivatives as SMO inhibitors
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2018003563A (es) Nuevos compuestos.
MX2016014436A (es) Derivados de heterociclil-butanamida.
IN2014MU00303A (es)
MX2017015936A (es) Nueva composicion farmaceutica que comprende agentes tensioactivos no ionicos.
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MX2020000135A (es) Nuevos compuestos de quinolinona.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2021007853A (es) Compuestos de tienopiridinona.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
IN2013MU03118A (es)
PH12021552389A1 (en) Quinoline derivatives and their use for the treatment of cancer
HK1246796A1 (en) Bicyclic heterocycles as fgfr4 inhibitors